MarcSabatineMD

Cardiology • Boston, MA

Adult Congenital Heart Disease

Associate Professor of Medicine, Brigham and Women's Hospital.

Join to view full profile

Dr. Sabatine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sabatine's full profile

Already have an account?

Office
75 Francis St
Brigham And Womens Hospital Cardiovascular Division
Boston, MA 02115
Phone+1 617-278-0145

Education & Training

Massachusetts General HospitalFellowship, Cardiovascular Disease, 1995 - 2002
Massachusetts General HospitalResidency, Internal Medicine, 1995 - 1998
Harvard Medical SchoolClass of 1995

Certifications & Licensure

MA State Medical License 2000 - 2025
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2012
Fellow (FACC) American College of Cardiology

Clinical Trials

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
Completed
Phase 3
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Start of enrollment: 2020 Aug 05
Completed
Phase 4

Publications & Presentations

PubMed

Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial.
Prakriti Gaba, Robert S Rosenson, J Antonio G López, Gerald F Watts, Thorsten M Leucker
Journal of the American College of Cardiology. 2024-12-04
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
John W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, Zi Michael Miao, Silvio E Inzucchi
European Heart Journal. 2024-11-21
Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study.
Gurleen Kaur, Robert S Rosenson, Baris Gencer, J Antonio G López, Norman E Lepor
European Heart Journal. 2024-11-20

Journal Articles

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction
Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition
Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
PCSK9 Inhibition—A Tale of 2 Potential Treatment Opportunities—Reply
Brian A Bergmark, Marc S Sabatine, JAMA Cardiology
Association of Hospital-Level Differences in Care with Outcomes Among Patients with Acute ST-Segment Elevation Myocardial Infarction in China
Xuan Zhang, Hui Sun, Marc S Sabatine, Stephen D Wiviott, JAMA Network Open
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy
Prakash Deedwania, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines
Nicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction
Christopher E Kurtz, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes
Akshay S Desai, Mikhail N Kosiborod, Marc S Sabatine, JAMA
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D Wiviott, Marc S Sabatine, Christian T Ruff, Marc P Bonaca, Deepak L Bhatt, Darren K McGuire, The New England Journal of Medicine
PCSK9 Inhibitors: Clinical Evidence and Implementation
Marc Sabatine, MD, Nature
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
Join now to see all

Lectures

PCSK9 Inhibitors: What We Know What We Don't Know and Where are We Going?
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
Join now to see all

Press Mentions

First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current AnticoagulantsJanuary 3rd, 2023
Statins Boost Glycemia Slightly, but CVD Benefits PrevailNovember 14th, 2022
Amgen Presents New Repatha® (Evolocumab) Data at Aha 2022November 7th, 2022
Join now to see all